University of Minnesota
Synthesis and Evaluation of Novel Quinazolinone Analogs as Potential RAD51 Inhibitors
Abstract
dc:description.abstractIn BRCA1/2 mutated cancer, homologous recombination is deficient due to the critical role BRCA1/2 proteins facilitate. PARP inhibitors take advantage of this by inhibiting single stranded DNA repair so that more double stranded DNA breaks occur. Several FDA approved PARPi are used in the clinic but resistance to these therapies is very common. This is due to the reactivation of HR from the mutation or re-expression of BRCA1/2 protein. RAD51 is a key protein in HR and is vital for DNA repair and PARPi resistance. Thus, inhibiting RAD51 can stop HR and may overcome resistance in PARPi resistant cancers. Literature studies have identified promising RAD51 inhibitors but with unfavorable metabolic groups. We modified these structures to increase activity and improve the pharmaceutical properties through a structural activity relationship study. Several novel molecules were synthesized and evaluated with the MTT assay using 5 cancerous cell lines which include three breast cancer cell lines MDA-MB-231, 4T1 and 67NR and two pancreatic cancer cell lines MIA PaCa-2 and BxPC-3. Several synthesized candidates were found to have high nanomolar to low micromolar activity against these cancerous cell lines. Based on these studies, a lead candidate was identified, and a maximum tolerated dose study was also done for future anticancer efficacy studies. This study indicated that the lead derivative was well tolerated at therapeutic relevant doses.
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Wittmer, Matthew David
Subjects
dc:subject × 6Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Dc Identifier Citation
- Wittmer, Matthew David. (2024). Synthesis and Evaluation of Novel Quinazolinone Analogs as Potential RAD51 Inhibitors. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/282274.